General
Preferred name
vimseltinib
Synonyms
DCC-3014 ()
DP-6865 ()
P&D ID
PD133944
CAS
1628606-05-2
Tags
available
probe
drug candidate
Drug indication
Solid tumour/cancer
Drug Status
investigational
Max Phase
3.0
Probe info
Probe selectivity
protein-selective
Probe type
experimental probe
P&D approved
Probe targets
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION The chemical structure submitted to the WHO for the INN vimseltinib is identical to that of the investigational, oral CSF1R inhibitor DCC-3014, via a PubChem structure match. The compound is claimed as example 10 in Deciphera Pharmaceuticals' patent WO2014145025A2, in which KIT proto-oncogene inhibitory activity is also noted . Name to structure was formally disclosed in Caldwell et al. (2022) . Vimseltinib's selectivity is determined by its interactions within the switch control region of the CSF1R that regulates kinase conformational activation. (GtoPdb)
MOA Inhibitor (Chemical Probes.org)
Cell lines
1
Organisms
0
Compound Sets
11
Cayman Chemical Bioactives
ChEMBL Drugs
Chemical Probes.org
CZ-OPENSCREEN Bioactive Library
DrugBank
DrugMAP
Guide to Pharmacology
High-quality chemical probes
MedChem Express Bioactive Compound Library
PKIDB
Selleckchem Bioactive Compound Library
External IDs
11
Properties
(calculated by RDKit )
Molecular Weight
431.21
Hydrogen Bond Acceptors
9
Hydrogen Bond Donors
1
Rotatable Bonds
6
Ring Count
4
Aromatic Ring Count
4
cLogP
3.56
TPSA
99.75
Fraction CSP3
0.26
Chiral centers
0.0
Largest ring
6.0
QED
0.5
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Pathway
Protein Tyrosine Kinase/RTK
Target
c-Fms
c-Kit
c-Kit,CSF-1R
CSF1R
Target class
Kinase
Target subclass
TK
Source data